$ MNKD has catalysts that will take this stock much higher. linked info.
3 Speculative Biotech Companies Primed to Pop - Motley Fool
By Keith Speights
Ready for a giant leap
MannKind (NASDAQ: MNKD ) stands closer than ever to taking a giant leap for its shareholders. The company expects to conclude two clinical studies in the next few months for its inhalable insulin product, Afrezza. Results from both studies will be announced in August. MannKind hopes to submit for FDA approval by October.
While the last decade proved to be a roller coaster ride for investors, 2013 is looking great for MannKind so far in anticipation of good news from the clinical studies. I fully expectthat anticipation to be rewarded. The biotech encountered plenty of bumps and bruises in past attempts to gain approval for Afrezza, but this time MannKind should prevail in its quest